A Scalable Blueprint for Multi-Serotype AAV Programs

Executive Summary

A platform-based approach to AAV process development provides a significant advantage for programs utilizing multiple serotypes or developing multiple candidates. By leveraging a core, serotype-agnostic manufacturing blueprint, timelines from research to GxP-compliant production can be accelerated, targeting an 18-24 month path to IND. This methodology minimizes process variability, simplifies technology transfer, and allows for rapid adaptation for specific vector constructs, de-risking the path to clinical manufacturing within our >100,000 sq ft facility.

AAV Process Development: From Bespoke to Blueprint

Developing a manufacturing process for a single AAV vector is a resource-intensive undertaking. Creating distinct processes for multiple serotypes or candidates within a portfolio multiplies this challenge, introducing variables that can delay programs and complicate regulatory submissions. A platform approach moves away from this inefficient model.

We have established a core production methodology for both adherent and suspension cultures that serves as a validated foundation. This allows our scientific team to focus on the targeted refinements needed for your specific vector, whether it is a clinically validated capsid like AAV8 or a custom-engineered vector. This established methodology provides strategic process blueprints accelerating technology transfer to GxP environments.

Mitigating Immunogenicity Through Process Control

The potential for pre-existing or vector-induced neutralizing antibodies is a known factor in AAV-based therapeutic development. Research on natural AAV exposure highlights the complexity of antibody responses, where a single event can induce broad cross-neutralizing activity against multiple serotypes (PMID: 27314914).

While the vector capsid is the primary immunological determinant, process-related impurities can also influence the host immune response. A platform process provides stringent control over product purity, consistently minimizing levels of empty capsids, host cell proteins, and residual plasmid DNA. This manufacturing consistency ensures that the immunogenicity profile observed in preclinical toxicology studies is a true reflection of the vector itself, not an artifact of process variability.

Wonderful services. Excellent team to work with. Vast knowledge in all aspects of vector production and analytics.
— Biotech Partner

Platform Advantages for Viral Vector Portfolios

For sponsors developing multiple AAV-based assets, the benefits of a platform process extend beyond a single program.

• Simplified Comparability: When advancing a next-generation candidate with a modified capsid or payload, using the same manufacturing platform simplifies the demonstration of analytical comparability to regulatory bodies.

• Predictable Timelines: The operational familiarity with the platform allows for more accurate forecasting of production timelines and material availability for IND-enabling studies.

• Knowledge Compounding: Process knowledge and characterization data from each vector produced on the platform are leveraged to further refine and improve the core process over time.

This approach reflects a transition from treating each vector as a unique manufacturing challenge to managing a portfolio of assets through a unified, data-driven system. This continuity is maintained by the same scientific teams that managed vector production at the Penn Vector Core, ensuring a depth of experience that supports a 100% successful IND rate for programs since 2019, with the Franklin Biolabs brand itself launching in 2024.